Exelixis/EXEL
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX
About Exelixis
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Ticker
EXEL
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Alameda, United States
Employees
1,310
Website
www.exelixis.com
Exelixis Metrics
BasicAdvanced
$6.5B
Market cap
33.93
P/E ratio
$0.65
EPS
0.57
Beta
-
Dividend rate
Price and volume
Market cap
$6.5B
Beta
0.57
Financial strength
Current ratio
3.465
Quick ratio
3.259
Long term debt to equity
9.467
Total debt to equity
9.467
Management effectiveness
Return on assets (TTM)
4.30%
Return on equity (TTM)
8.76%
Valuation
Price to earnings (TTM)
33.93
Price to revenue (TTM)
3.75
Price to book
3.07
Price to tangible book (TTM)
3.17
Price to free cash flow (TTM)
37.36
Growth
Revenue change (TTM)
10.98%
Earnings per share change (TTM)
38.78%
3-year revenue growth
21.45%
3-year earnings per share growth
47.08%
What the Analysts think about Exelixis
Analyst Ratings
Majority rating from 21 analysts.
Exelixis Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$425M
-11.34%
Net income
$37M
-56.37%
Profit margin
8.77%
-50.79%
Exelixis Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.25
-
$0.27
$0.12
-
Expected
$0.16
$0.10
$0.21
$0.24
$0.30
Surprise
56.25%
-
27.08%
-49.65%
-
Exelixis News
AllArticlesVideos
Insider Buying Heats Up at Fracker, Aircraft and Boat Makers, and More
24/7 Wall Street·1 month ago
Exelixis to Present at the William Blair 44th Annual Growth Stock Conference
Business Wire·1 month ago
Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Exelixis stock?
Exelixis (EXEL) has a market cap of $6.5B as of July 04, 2024.
What is the P/E ratio for Exelixis stock?
The price to earnings (P/E) ratio for Exelixis (EXEL) stock is 33.93 as of July 04, 2024.
Does Exelixis stock pay dividends?
No, Exelixis (EXEL) stock does not pay dividends to its shareholders as of July 04, 2024.
When is the next Exelixis dividend payment date?
Exelixis (EXEL) stock does not pay dividends to its shareholders.
What is the beta indicator for Exelixis?
Exelixis (EXEL) has a beta rating of 0.57. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Exelixis stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.